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Abstract
Background: Our objective was to assess the histological changes in mammary glands of the
female Wistar-Furth rat as a result of low dose exposure to N-nitrosomethylurea (NMU).
Methods: Groups of 30–40 virgin female rats of between 49–58 days old received a single injection
of 10, 20, 30 or 50 mg NMU/kg body weight (BW). A group of 10 control rats received 0.9% NaCl
solution only. The formation of palpable mammary gland tumors was assessed weekly and, upon
sacrifice at 12, 22 and 25–30 weeks after treatment, we performed a comprehensive histological
analysis of all mammary gland lesions and tumors.
Results: Alongside the predicted increase in tumor number and decrease in tumor latency with
increasing NMU dose, we observed a number of microscopic lesions and other epithelial
abnormalities in the mammary glands for all NMU doses. Two types of non-neoplastic histological
changes were observed in rats exposed to 10 or 20 mg NMU/kg BW: namely, (i) an increase in the
number of acinar structures often accompanied by secretion into the lumen which is normally
associated with pregnancy and lactation, and (ii) an increase in the number of epithelial cells
sloughed into the lumen of the epithelial ducts.
Conclusion: This study establishes a baseline for low-dose exposure and defines the histological
features in the mammary gland resulting from NMU exposure. Furthermore, this system provides
an ideal platform for evaluating the relative susceptibility of animals protected from, or predisposed
to, developing cancer through environmental influences.
Background
The induction of mammary tumors in female rats of sus-
ceptible strains by N-nitrosomethylurea (NMU) is an
established model which has been used for several dec-
ades [1]. It is the simplest method for generating a nearly
complete surrogate model of human mammary carcino-
mas that closely mimics the human disease in terms of
tumor histology and hormone dependence [1]. NMU is a
direct acting carcinogen that unlike other carcinogens
such as 7,12-dimethylbenz [a]anthracene (DMBA) [2,3]
does not require the metabolic activation steps in order to
form DNA adducts and has a very short half-life [4]. In
addition, NMU exposure results in point mutations in
codon 12 of the Ha-ras-1 gene [5]. A single NMU injection
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will produce 100% incidence of mammary tumors in sus-
ceptible rats and its specificity for the mammary and sali-
vary glands is unexplained. Accordingly, numerous
studies have been conducted using NMU to generate
mammary gland tumors in several rat strains [6-11]
including Wistar-Furth [11]. Most of these studies have
used a standard dose of 50 mg NMU/kg body weight
(BW) administered between 50–60 days of age. This dose
is relevant for applications in which a rapid induction of
tumors with a high yield is desired.
Additionally, NMU has been used to test whether animals
are predisposed to neoplasia and/or susceptible to muta-
gens [12,13]. Perinatal exposure to estrogenic compounds
induces intraductal hyperplasias in the mammary gland
[14] that do not often become palpable tumors but might
be induced to follow this fate by a low dose NMU chal-
lenge [12]. When using NMU as a challenge to uncover
the carcinogenic effects of fetal exposure to estrogens, it is
necessary to discriminate between the contributions of
each agent to the histological lesions observed. "Dose-
response" experiments using NMU have been performed
in several different rat strains [7-9,11] but did not report
histological analyses of the NMU-exposed mammary
glands. In addition, when considering the differences in
strain susceptibility to chemical carcinogens, a new dose
response curve should be run in the strain of interest.
Herein, we conducted an NMU dose-response experiment
with Wistar-Furth strain rats in which they were exposed
to 10, 20, 30 or 50 mg NMU/kg BW. We used 50 mg
NMU/kg BW as the highest dose because previous work
has shown this dose as causing the highest incidence of
mammary gland tumors with the lowest level of adverse
effects [8,15], and also because most work in this experi-
mental model has been conducted with this dose. We per-
formed a comprehensive histological analysis of all
mammary gland lesions and tumors found at each NMU
dose in an attempt to identify what structural changes
occur in the mammary gland before and after palpable
tumors become evident.
Methods
Animals
Virgin female Wistar-Furth rats obtained from Harlan
Sprague Dawley, Inc., (Indianapolis, IN) were maintained
in temperature- and light-controlled (14 h light, 10 h dark
cycle) conditions in the Tufts University School of Medi-
cine Division of Laboratory Animal Medicine. All experi-
mental procedures were approved by the Tufts University-
New England Medical Center Animal Research Commit-
tee in accordance with the Guide for Care and Use of Lab-
oratory Animals.
Tumor Induction and Detection
NMU was purchased from Sigma Aldrich Chemical Com-
pany (St Louis, MO) and was dissolved in warm 0.9%
NaCl acidified to pH 5.0 with acetic acid (vehicle). Rats
between 49 and 58 days of age received a single intraperi-
toneal (i.p.) dose of 10, 20, 30 or 50 mg NMU/kg BW.
Solutions were used within 15 minutes of preparation.
Control rats received a single i.p. injection of vehicle. In
all cases an injection volume of 0.2 ml was used.
Palpation of the thoracic and abdominal-inguinal mam-
mary glands was performed weekly starting at four weeks
post-NMU injection (p.i.) to determine the incidence and
latency of tumor formation. When tumors reached a size
of approximately 1 cm3 before the pre-determined time
point for tissue harvesting, they were surgically removed
and the rats were returned to the experiment. Tumor inci-
dence was calculated as the number of animals with at
least one palpable tumor or microscopic tumor lesion
compared to the total number of animals in the group.
Latency was defined as the time between the NMU injec-
tion and the detection of the first palpable tumor.
Tissue harvest
Rat mammary glands were collected at 12, 22 and 25–30
weeks p.i. This was achieved by allocating the animals
from all doses into 2 tissue harvest groups. In group 1 (n
= 4–6), the 4th and 5th right abdominal-inguinal mam-
mary glands were surgically removed under anesthesia 12
weeks p.i. At 22 weeks p.i. these animals were sacrificed
and the contralateral glands were collected. Previous dose-
response studies [8,9,11] indicated that 12 weeks p.i.
should correlate with few palpable tumors in the lower
NMU doses, while 22 weeks p.i. was selected as a mid-
point between 12 weeks p.i. and 30 weeks p.i., our
intended end point for the experiment.
Animals allocated to group 2 (n = 30–40) were sacrificed
at 25 weeks p.i. (50 mg NMU/kg BW) or 30 weeks p.i. (all
other doses) and both the 4th and 5th abdominal-inguinal
mammary glands were collected. The animals treated with
50 mg NMU/kg BW were sacrificed earlier than the other
groups as palpable tumor incidence in this group reached
100% by 17 weeks p.i. Thus, rather than subjecting the
animals to surgical removal of these fast-growing large
tumors and possible post-operative complications, the
animals were euthanized.
Whole mounts and histology
Tumors larger than 0.5 cm in diameter were removed
from the mammary gland prior to preparing the whole
mount. Tumors were fixed overnight in 10% phosphate
buffered formalin and processed for paraffin embedding
as described previously [15]. Sections (5 μm) were stained
with Hematoxylin and Eosin (H&E).
The whole mounts were prepared following protocols
described previously [16]. In brief, the mammary glands
were removed and spread on a 75 × 50 × 1 mm glass slideBMC Cancer 2009, 9:267 http://www.biomedcentral.com/1471-2407/9/267
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(Fisher Scientific, Pittsburgh, PA). They were fixed over-
night in 10% phosphate buffered formalin, dehydrated in
alcohol, cleared of fat with toluene, rehydrated and
stained with Carmine Alum. After staining, the whole
mounts were dehydrated as described above, cleared in
xylene, and bagged in Kpak® SealPak heat-seal pouches
(Kpak Corp., Minneapolis, MN) with methyl salicylate.
Microscopic lesions were excised from the whole mounts
and embedded in paraffin for histological evaluation. Sec-
tions were stained with H&E to visualize the overall mor-
phology and with Trichrome stain (Masson) to assess the
collagen distribution in the stroma. In addition, based on
their overall morphology certain lesions were selected to
undergo immunohistochemical staining using an anti-
body raised against α-lactalbumin (ABR Affinity Biorea-
gents, Golden, CO) to determine whether this milk
protein was expressed in these samples. In other sections,
immunostaining using an antibody raised against pan-
keratin (Sigma Aldrich) was used to identify the epithelial
cells within the mammary gland.
Histological sections were visualized with an Axioskop 2
Plus microscope (Carl Zeiss, Hallbergmoos, Germany)
whereas whole mounts were analyzed with a Stemi-
2000C stereomicroscope (Carl Zeiss). Images were cap-
tured with an AxioCam HR color digital camera (Carl
Zeiss) and the Axiovision software (version 4.3).
Statistical analysis
All statistical analysis was performed using SPSS software
(Chicago, IL). The average tumor latency period is
depicted in a Kaplan-Meier curve and was analyzed by a
log rank test. The tumor and lesion incidences were ana-
lyzed by chi-square. Data were expressed as mean ± SEM.
Data were considered statistically significant when p <
0.05.
Results
Incidence of palpable tumors
Figure 1A shows that when the NMU dose was raised from
10 mg to 50 mg NMU/kg BW, the palpable tumor inci-
dence increased accordingly, as did the average tumor
number per rat (Figure 1B). When the dose was increased
from 10 mg NMU/kg BW through 50 mg NMU/kg BW
there was an approximate 6-fold increase in tumor
number.
Tumor latency
The first palpable tumors were evident at 24, 14, 8 and 6
weeks p.i. for the animals exposed to 10, 20, 30 and 50 mg
NMU/kg BW, respectively. In addition, we calculated the
average tumor latency for each group and found a
decrease in tumor latency with increasing NMU dose. The
average latency in weeks was 26.00 ± 2.00 for 10 mg
NMU/kg BW, 22.57 ± 1.85 for 20 mg NMU/kg BW, 15.85
± 1.32 for 30 mg NMU/kg BW and 10.48 ± 0.40 for 50 mg
NMU/kg BW.
Figure 2 shows a Kaplan-Meier graph depicting the tumor
latency period for all doses. A log rank analysis showed a
significantly shorter latency in the group treated with 50
mg NMU/kg BW compared to all other groups (p <
0.0000). Additionally, latency was significantly shorter in
the 30 mg NMU/kg BW group than in the 20 mg NMU/kg
BW (p < 0.0000) and 10 mg NMU/kg BW (p < 0.0000)
groups. There was no significant difference in tumor
latency between the 10 mg NMU/kg BW and 20 mg NMU/
kg BW dose.
Incidence of mammary gland tumors developing in Wistar- Furth female rats following different doses of NMU Figure 1
Incidence of mammary gland tumors developing in 
Wistar-Furth female rats following different doses of 
NMU. A: total tumor incidence; B: Average number of mam-
mary gland tumors developing in female rats following differ-
ent doses of NMU. n = 29–40/group.BMC Cancer 2009, 9:267 http://www.biomedcentral.com/1471-2407/9/267
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Histopathology of tumors
Histological evaluation of the tumors revealed that the
two lower doses (10 mg NMU/kg BW and 20 mg NMU/kg
BW) exclusively generated ductal carcinomas in situ
(DCIS). Compared to tumors formed after exposure to 10
mg NMU/kg BW, tumors generated following exposure to
20 mg NMU/kg BW tended to show more features charac-
teristic of an invasive phenotype such as subtle tumor
growth projections into the normal tissue. Tumors from
animals exposed to 30 mg NMU/kg BW were predomi-
nately DCIS with some showing invasive tendencies. In
addition, one animal produced a DCIS with a fibroade-
noma while another generated a fibroadenoma with an
adenocarcinoma. Histology similar to the 30 mg NMU/kg
BW group was seen in tumors excised from animals dosed
with 50 mg NMU/kg BW.
Aberrant structures in whole-mounted mammary glands
Microscopic inspection of the abdominal-inguinal whole-
mounted mammary glands revealed a number of lesions
and other epithelial abnormalities at all doses tested
(Table 1). For the 12 and 22 weeks p.i. groups, the data are
presented as incidence per gland as the left-side abdomi-
nal-inguinal mammary glands were surgically removed at
12 weeks after which the contralateral gland was removed
at sacrifice (22 weeks). This paired data set showed that
the aberrant structure incidence increased with NMU
dose. In addition, their incidence increased over time with
more aberrant structures at 22 weeks compared to 12
weeks for all doses except 10 mg NMU/kg BW. No lesions
or other abnormal structures were identified in the mam-
mary glands from rats treated with 10 mg NMU/kg BW at
these early time points.
Thus, at the end of the experiments (25 weeks p.i. for 50
mg NMU/kg BW, 30 weeks p.i. for all other groups) anal-
ysis of left and right side abdominal-inguinal mammary
glands for each animal showed a similar NMU dose-
dependant incidence increase (Table 1). The incidence of
abnormalities in the 50 mg NMU/kg BW group was signif-
icantly higher than in all other groups (p < 0.005) while
the incidence in the 10 mg NMU/kg BW group was statis-
tically lower than in the 20 mg NMU/kg BW (p = 0.02)
and 30 mg NMU/kg BW (p = 0.003) groups. Interestingly,
this time point was the only one where we observed aber-
rant structures in the whole-mounted mammary glands of
animals from the 10 mg NMU/kg BW group where the
incidence reached 5.3%.
Classification of aberrant microscopic structures
To better understand the events occurring in the mam-
mary gland before palpable tumors became evident, we
performed histological evaluations of the aberrant struc-
tures found in the whole-mounted mammary glands from
all doses and time points. As the 10 mg and 20 mg NMU/
kg BW groups gave the lowest incidence of aberrant struc-
tures in whole mounted mammary glands (5.3% and
24.3% respectively), we performed histological evalua-
tions of all the aberrant structures found in these whole
mounts. In addition, we evaluated all lesions and other
abnormalities found at the two higher doses (30 mg and
50 mg NMU/kg BW) at 12 and 22 weeks p.i. Finally, we
surveyed a sub-set of aberrant structures from the two
higher NMU doses at the last sacrifice point (25 and 30
weeks, respectively) to determine whether the histological
classification of these structures changed as the carcino-
genic process progressed.
10 and 20 mg NMU/kg BW group
A number of morphological changes were observed in
these glands as outlined in Table 2 and Figure 3. The most
prevalent abnormality for both NMU doses was a change
in the structure of the tissue that closely resembled a preg-
nant or lactating mammary gland phenotype (Figure 3C
and 3D). That is, compared to a normal control mammary
gland (Figure 3A and 3B), some mammary glands con-
tained an increased number of acini (Figure 3E and 3F). In
some cases, the epithelium had also further differentiated
into a lobular unit composed of acini which were filled
with secretion (Figure 3E and 3F). Closer examination
revealed that the secretion, which appears pink in the
H&E staining, contained fatty globules characteristic of
milk production (Figure 3F).
These lactational changes in the virgin mammary glands
were further characterized by performing immunostain-
ing using an antibody raised against α-lactalbumin, a milk
protein. In the glands exhibiting the lactating phenotype
we found that the cells within the lobular units and the
secretion within the ducts showed positive immunostain-
ing (Figure 4A). A similar staining pattern was seen in a
positive control lactating rat mammary gland (Figure 4B),
Incidence of palpable tumors as a function of time after NMU  injection Figure 2
Incidence of palpable tumors as a function of time 
after NMU injection.BMC Cancer 2009, 9:267 http://www.biomedcentral.com/1471-2407/9/267
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confirming that the virgin glands had indeed altered their
phenotype and were producing milk. Accordingly, a con-
trol virgin mammary gland did not stain with this anti-
body (Figure 4C) confirming that the antibody reacted
specifically with the α-lactalbumin antigen.
Other morphological changes we observed were DCIS
(Figure 3G and 3H) and hyperplastic ducts (Figure 3I); the
latter were defined as ducts containing more than 3 layers
of epithelial cells [14]. Finally, some ducts had an increase
in the number of cells within the lumen of the epithelial
ducts (Figure 3J). Immunostaining for pan-keratin
revealed that this cell population included epithelial cells
which had apparently sloughed into the lumen from the
epithelial duct walls (data not shown). This phenomenon
was not observed in control tissue.
In order to determine whether the observed structural epi-
thelial changes were accompanied by changes in the
mammary gland stroma we stained for collagen content
in our samples using Masson's Trichrome method. There
was little collagen deposition around the acini of the
glands exhibiting the lactating phenotype (Figure 5A); this
pattern resembled that found in the positive control lac-
tating rat mammary gland (Figure 5B). In tissues showing
an increased number of acini, collagen deposition was
most pronounced around the ducts and was relatively low
around the acinar structures (Figure 5C and 5D). Some
collagen was deposited around the hyperplastic and DCIS
structures (Figure 5E); the DCIS also showed an increased
deposition of collagen within the tumor (Figure 5F).
Ducts containing the sloughed epithelial cells in the
lumen were surrounded by stroma containing more colla-
gen (Figure 5G) when compared to ducts from normal
glands (Figure 5H).
Interestingly, no abnormal structures were seen in the ani-
mals injected with 10 mg NMU/kg BW which had palpa-
ble tumors. A similar pattern was observed in rats injected
with 20 mg NMU/kg BW with only one exception: a pal-
pable tumor and lactational change structure were found
in one rat of this group.
30 and 50 mg NMU/kg BW group
Neoplastic and non-neoplastic features were observed in
the mammary glands of rats treated with 30 mg or 50 mg
NMU/kg BW as early as 12 weeks p.i. (Table 2 and Figure
3). In the 50 mg NMU/kg BW group, DCIS and hyperpla-
sias were observed at 12 weeks p.i. alongside other struc-
tural alterations, such as increased numbers of epithelial
structures resembling acini. At 22 weeks p.i., hyperplastic
ducts and acini persisted. In addition, we observed secre-
tion in ducts with otherwise normal histology while sev-
eral ducts were found to have undergone morphological
changes making their appearance resemble those found in
a lactating gland. These changes were similar to those
observed at the two lower doses of NMU. At 25 weeks p.i.
the majority of abnormalities within the mammary gland
were diagnosed as DCIS. However, there were also a
number of benign lesions (fibroadenoma and papilloma
types, Figure 3K) and hyperplastic ducts. Luminal secre-
tion (Figure 3L) and sloughing of epithelial cells into the
duct were also present.
Secretion into the ducts was also observed in the mam-
mary glands from animals treated with 30 mg NMU/kg
BW at 12 and 22 weeks p.i.; however, morphological
changes consistent with lactation were only noted at later
time points (22 and 30 weeks p.i.). These changes were
also accompanied by a transient increase in the number of
acini within the mammary gland at 22 weeks p.i. At this
dose, ductal hyperplasias were also observed although
these were only apparent at the earliest and latest time
points. Furthermore, DCIS were apparent at this dose at
the later time points, while benign fibroadenoma lesions
were found at 30 weeks p.i. only.
Table 1: Incidence of microscopic lesions and other microscopic abnormalities in NMU-treated whole mounted abdominal-inguinal 
mammary glands
NMU dose (mg/kg BW) 12 weeks incidence (%) Ω 22 weeks incidence (%)Ω 25–30 weeks incidence (%) §
0 0/6 (0) 0/5 (0) 0/9 (0) ab
10 0/6 (0) 0/6 (0) 2/38 (5.3) a
20 0/6 (0) 1/6 (16.6) 9/37 (24.3) bc
30 2/5 (40.0) 3/5 (60.0) 9/27 (33.3) c
50 4/5 (80.0) 3/4 (75.0) 21/26 (80.8) d
Ω indicates that the incidence was calculated 'per mammary gland' whereas § denotes the incidence calculated using abdominal-inguinal mammary 
glands from the left and right side of each animal. Different superscripts denote statistically significant differences (p < 0.05).BMC Cancer 2009, 9:267 http://www.biomedcentral.com/1471-2407/9/267
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At these doses of NMU, Trichrome staining of tissue
exhibiting a lactating phenotype, increased number of
acini, hyperplasias or DCIS revealed similar results to
those reported for the two lower NMU doses. In addition,
in tissues with ducts showing secretion into the lumen,
collagen deposition was most pronounced around the
larger ducts.
For the 30 mg NMU/kg BW group, similar to the lower
NMU doses, aberrant structures were usually observed in
animals that did not develop palpable tumors and con-
versely, animals that developed palpable tumors did not
show any other obvious epithelial abnormalities. There
was only oneexception: a palpable tumor and ductal
hyperplasia were found in the same animal. Palpable
tumor incidence reached 100% in the 50 mg NMU/kg BW
animals, thus all aberrant structures found in this group
were coincident with tumor formation.
Discussion
This study attempts to fill the need for an in depth his-
topathological analysis of the mammary gland in Wistar
Furth rats after exposure to low doses of NMU. It has been
reported that female rats from susceptible strains develop
mammary tumors when exposed to 50 mg/kg BW of the
commonly used carcinogen, NMU [1,9,16-18]. Herein,
rats from the susceptible Wistar-Furth strain were exposed
to NMU at lower, and presumably, less carcinogenic
doses. Following exposure to low doses of NMU (10 mg
and 20 mg/kg BW), Wistar-Furth rats developed far fewer
mammary gland carcinomas than those observed in ani-
mals treated with higher doses of carcinogen (30 mg and
50 mg NMU/kg BW). Furthermore, the latency to the first
palpable tumor for the low dose animals was substantially
longer than in those receiving higher doses of NMU (14–
24 weeks vs 6–8 weeks, respectively). However, a number
of microscopic abnormalities were apparent in whole
mounted mammary glands collected from the low dose
animals while histological analysis showed that these
ranged from simple ductal hyperplasias and DCIS to non-
neoplastic structural changes. In the animals exposed to
10 mg or 20 mg NMU/kg BW, two distinct types of histo-
logical changes were observed, namely, (i) an increase in
the number of acinar structures often accompanied by
secretion into the lumen which is normally associated
with pregnancy and lactation, and (ii) an increase in the
number of epithelial cells sloughing into the lumen of the
epithelial ducts.
There were also notable changes in collagen deposition
associated with these structures compared to those seen in
the normal rat mammary gland. The presence of non-neo-
plastic changes and alterations in collagen deposition are
remarkable as they represent changes in tissue architec-
ture. This is consistent with those theories of carcinogene-
H+E staining of mammary gland microscopic lesions and  other microscopic abnormalities Figure 3
H+E staining of mammary gland microscopic lesions 
and other microscopic abnormalities. When compared 
to normal mammary gland (A, B), some of the glands show 
an increased number of acini which are normally only seen 
during pregnancy and lactation (C, D). Ducts that have fur-
ther differentiated into lobular units with secretion are strik-
ing (E, F). Neoplasias include DCIS (G, H) and ductal 
hyperplasias (I). Sloughing of epithelial cells into the duct (J) is 
also observed. At higher doses of NMU (30 mg and 50 mg/kg 
BW), benign fibroadenomas and papillomas (K) and secretion 
into the duct (L) are observed. Scale bar: 50 μmBMC Cancer 2009, 9:267 http://www.biomedcentral.com/1471-2407/9/267
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sis that stress the role of tissue interactions in neoplastic
development [17-19].
Changes in mammary gland architecture have been noted
with other treatments. For example, our previous studies
revealed that rodents exposed perinatally to the xenoes-
trogen bisphenol A showed changes in mammary gland
architecture in adulthood when they developed intraduc-
tal hyperplasias with epithelial cells present inside the
ductal lumen [20]. Furthermore, these bisphenol A-
exposed animals exhibited changes in collagen localiza-
tion as early as embryonic day 18 compared to unexposed
control animals [21]. Also, it was observed that certain
biochemical alterations of the extracellular matrix (e.g. by
the addition of laminin) affected the expression of milk
proteins in the mammary gland [22].
A reduced-dose NMU model provides an ideal platform
for evaluating the tumor susceptibility of the rat mam-
mary gland, and provides a baseline that can be used to
model and predict the response to an NMU challenge to
animals which are predisposed to developing cancer due
to environmental insults. Based on the empirical finding
that 10 mg and 20 mg NMU/kg BW caused more than a
50% lower tumor incidence compared to 50 mg NMU/kg
BW (Figure 1; Table 1), and a significant increase in
latency, we consider both low doses as suitable for use in
future studies designed to evaluate whether certain treat-
ments increase the propensity to mammary cancer.
The present studies highlight the importance of consider-
ing other, more subtle, effects caused by carcinogen expo-
sure, such as the formation of microscopic dysplastic and
neoplastic lesions. It is important to note that both the
microscopic analysis and the length of this study showed
findings that could have been overlooked in shorter stud-
ies and in those using only palpation as the measured
endpoint. For instance, out of 40 animals in the lowest
dose of NMU only 2 exhibited palpable tumors, however
2 other animals in this group developed non-neoplastic
lesions. We conclude that all doses used in this study
showed some carcinogenic effect and therefore a true
"non-carcinogenic" NMU dose could not be defined.
Studies claiming to use such a dose should be interpreted
with caution [23,24].
A dose-response study in Sprague-Dawley rats revealed
that the number of tumors increased and the latency
decreased when the dose was increased from 25 mg
NMU/kg BW to 75 mg NMU/kg BW [7]. No differences in
tumor incidence, number or latency were noticed
between animals injected with 50 mg NMU/kg BW at 28,
35 or 42 days of age. This study reinforces the importance
of considering the rat strain selected when interpreting
data given that the Sprague-Dawley rats injected with 50
mg NMU/kg BW at 42 days of age showed a lower tumor
incidence and tumor burden than the Wistar-Furth rats
used in our study. Similarly, an additional dose-response
study highlights the importance of the route of NMU
exposure as the Sprague-Dawley rats receiving an intrave-
nous infusion of NMU at 50 days of age seemed to
develop tumors faster than those Wistar-Furth rats in this
study that were injected intraperitoneally; nevertheless,
the overall tumor burden appeared similar [9]. Finally, we
wish to highlight that this work characterizes the response
of an inbred rat strain offering the possibility of using het-
erotypic tissue recombinations to better understand the
role of the various mammary gland cell populations dur-
ing the carcinogenic process [15].
Conclusion
The results presented herein indicate that when rats from
a susceptible strain are injected with a low dose of the car-
cinogen NMU, such as 10 mg/kg BW, and they are moni-
tored for up to 7 months after exposure, they are still
capable of developing mammary tumors. Thus, we have
Table 2: Classification of microscopic lesions and other microscopic abnormalities: low dose NMU-treated whole mounted mammary 
glands
12 weeks 22 weeks 25 and 30 weeks§
Dose
(mg/kg BW)
10 20 30 50 10 20 30 50 10 20 30 50
Lactational change 0 0 0 0 0 0 1 2 2 4 1 0
Increased acini # 0 0 0 3 0 1 1 1 0 1 0 0
H y p e r p l a s i a 00110002 0 3 3 1
D C I S 00010110 0 2 71 8
§30 mg/kg BW animals were sacrificed at 30 weeks p.i. whereas 50 mg/kg BW animals were sacrificed at 25 weeks p.i. One abnormal structure per 
animal was selected for analysis at these time points compared to all structures being analyzed for all other groups.BMC Cancer 2009, 9:267 http://www.biomedcentral.com/1471-2407/9/267
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Immunolocalization of α-lactalbumin in mammary glands Figure 4
Immunolocalization of α-lactalbumin in mammary 
glands. In glands with the lactating phenotype (A), α-lactal-
bumin was localized to cells in the lobular units (arrowheads) 
and the secretion within the ducts. The positive control lac-
tating mammary gland showed similar staining (B), while the 
normal virgin mammary gland was negative (C). Scale bar: 50 
μm
Deposition of collagen (blue) in mammary glands of rats  stained with Masson's Trichrome Figure 5
Deposition of collagen (blue) in mammary glands of 
rats stained with Masson's Trichrome. In glands with 
the lactating phenotype (A) and increased number of acini (C 
and D), collagen was found surrounding larger ducts (arrow-
heads) and not associated with acinar structures (arrows); 
this pattern was also evident in positive control lactating 
mammary gland (B). Collagen surrounded DCIS structures 
(E) and was found within the carcinoma (F). Ducts containing 
sloughed epithelial cells showed more collagen deposition 
surrounding the duct (G) than that seen in normal tissue (H). 
Scale bar: 50 μmBMC Cancer 2009, 9:267 http://www.biomedcentral.com/1471-2407/9/267
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now established a useful "baseline effect" in the mam-
mary gland against which any treatment aimed at increas-
ing or decreasing tumor susceptibility in Wistar-Furth rats
can be compared. To our knowledge, this is the first in-
depth histological study of low dose NMU effects on the
rat mammary gland. Finally, considering differences in
tumor incidence and latency, we wish to stress the impor-
tance of conducting dose-response studies in the animal
strain of interest as susceptibility between rat strains varies
significantly.
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